15360-02-8 Usage
Uses
Used in Pharmaceutical Industry:
3-TERT-BUTOXYBENZOIC ACID is used as an organic building block for the preparation of orally efficacious benzothiazole amides. These amides act as TRPV1 antagonists, which are important in the treatment of various pain-related conditions and disorders. By targeting the TRPV1 receptor, these antagonists can help alleviate pain and provide relief to patients suffering from chronic or acute pain.
Used in Chemical Synthesis:
3-TERT-BUTOXYBENZOIC ACID is also used as a key intermediate in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure and functional groups make it a valuable component in the development of new molecules with specific properties and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 15360-02-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,3,6 and 0 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 15360-02:
(7*1)+(6*5)+(5*3)+(4*6)+(3*0)+(2*0)+(1*2)=78
78 % 10 = 8
So 15360-02-8 is a valid CAS Registry Number.
15360-02-8Relevant academic research and scientific papers
Inhibition of protein kinase C-driven nuclear factor-κB activation: Synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules
Peddibhotla, Satyamaheshwar,Shi, Ranxin,Khan, Pasha,Smith, Layton H.,Mangravita-Novo, Arianna,Vicchiarelli, Michael,Su, Ying,Okolotowicz, Karl J.,Cashman, John R.,Reed, John C.,Roth, Gregory P.
supporting information; experimental part, p. 4793 - 4797 (2010/10/19)
A unique series of biologically active chemical probes that selectively inhibit NF-κB activation induced by protein kinase C (PKC) pathway activators have been identified through a cell-based phenotypic reporter gene assay. These 2-aminobenzimidazoles represent initial chemical tools to be used in gaining further understanding on the cellular mechanisms driven by B and T cell antigen receptors. Starting from the founding member of this chemical series 1a (notated in PubChem as CID-2858522), we report the chemical synthesis, SAR studies, and pharmacological profiling of this pathway-selective inhibitor of NF-κB activation.
